Effect of a 2+1 schedule of ten-valent versus 13-valent pneumococcal conjugate vaccine on pneumococcal carriage: Results from a randomised controlled trial in Vietnam

Pneumococcal conjugate vaccines (PCVs) generate herd protection by reducing nasopharyngeal (NP) carriage. Two PCVs, PCV10 and PCV13, have been in use for over a decade, yet there are few data comparing their impact on Here we report effect carriage 2+1 schedule, compared with each other unvaccinated controls. Data from four groups within parallel, open-label randomised controlled trial Ho Chi Minh City contribute to this article. Three were receive schedule of (n = 250), PCV13 251), or two doses at 18 24 months (controls, n 197). An additional group 199) was recruited serve as controls months. NP swabs collected 2, 6, 9, 12, 18, analysed (blinded) pneumococcal This study aimed determine if differential carriage, secondary outcome the trial. We also describe serotype distribution among participants. Trial registration: ClinicalTrials.gov NCT01953510. Compared controls, reduced PCV10-type 45–62% pre-booster through age, PCV13-type 36–49% 12 age. directly other, differences between Vaccine serotypes accounted majority Both reduce vaccine serotypes. The introduction either would potential significant population. National Health Medical Research Council Australia, Bill & Melinda Gates Foundation.